Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics Inc (NEO) provides cutting-edge cancer diagnostic testing and clinical consultation services to healthcare providers worldwide. This news hub delivers timely updates on the company’s advancements in molecular oncology, regulatory milestones, and strategic partnerships shaping precision medicine.
Access authoritative coverage of NEO’s latest developments, including new test launches, laboratory accreditations, and peer-reviewed research insights. Investors and clinicians will find curated updates on earnings reports, biomarker discovery initiatives, and collaborations with leading cancer centers.
Key content areas include regulatory filings, technology partnerships, clinical study outcomes, and executive leadership updates. All news is vetted for accuracy and relevance to oncology professionals and stakeholders in precision diagnostics.
Bookmark this page for streamlined access to NeoGenomics’ evolving role in cancer care innovation. Check regularly for objective reporting on developments impacting diagnostic standards and patient outcomes across global healthcare systems.
NeoGenomics, Inc. (NASDAQ:NEO) announced that it will release its first quarter 2023 financial results on May 8, 2023, followed by a webcast and conference call at 4:30 p.m. Eastern Time. Interested investors can join the call via telephone or access it through the company's Investor Relations website. The company specializes in cancer genetics testing and offers a wide range of oncology-focused testing services. NeoGenomics operates CAP accredited and CLIA certified laboratories across the United States and internationally, serving a diverse clientele in the oncology field. This upcoming financial announcement is crucial for investors tracking the company's performance and strategic initiatives.
NeoGenomics, Inc. (NASDAQ: NEO), a prominent provider of cancer-focused genetic testing and oncology contract research services, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 11:00am ET. A live audio webcast will be accessible via the Investor Relations section of their website.
NeoGenomics specializes in cancer genetics testing, offering a wide range of testing options to assist healthcare providers in diagnosing and treating cancer. The company also supports pharmaceutical clients through clinical trials and drug development.
Headquartered in Fort Myers, Florida, NeoGenomics operates accredited laboratories across the U.S. and internationally. They are dedicated to connecting patients with transformative therapies while ensuring compliance with data protection laws.
NeoGenomics, Inc. (NASDAQ:NEO) has announced plans to present nine abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled for April 14-19 in Orlando, Florida. The presentations will showcase data on the company's advanced RaDaR liquid biopsy test, designed for detecting minimal residual disease (MRD). Dr. Shashikant Kulkarni, Chief Scientific Officer, highlighted the performance comparisons of RaDaR against other MRD tests, emphasizing the firm's commitment to innovation in cancer monitoring. Each abstract covers various aspects of cancer testing, including new methodologies and technological advancements in the field. RaDaR has received FDA Breakthrough Device Designation and is validated for use across multiple cancer types, enhancing NeoGenomics' service portfolio for oncologists and pharmaceutical partners.
FAQ
What is the current stock price of Neogenomics (NEO)?
What is the market cap of Neogenomics (NEO)?
